Last reviewed · How we verify
No domperidone
No domperidone is a Small molecule drug developed by Canadian Network for Observational Drug Effect Studies, CNODES. It is currently in Phase 2 development.
Domperidone has been studied as a treatment for conditions such as achalasia, gastroesophageal reflux disease (GORD), gastroparesis, and Parkinson's disease. It has been compared to esomeprazole in clinical trials for conservative management of these conditions.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | No domperidone |
|---|---|
| Sponsor | Canadian Network for Observational Drug Effect Studies, CNODES |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Domperidone and Risk of Serious Cardiac Events in Postpartum Women
- Domperidone and Risk of Sudden Cardiac Death
- Use of Domperidone for Treatment of Upper Gastrointestinal Disorders
- Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy (NA)
- Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS) (PHASE2)
- Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease (PHASE4)
- Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone
- An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- No domperidone CI brief — competitive landscape report
- No domperidone updates RSS · CI watch RSS
- Canadian Network for Observational Drug Effect Studies, CNODES portfolio CI
Frequently asked questions about No domperidone
What is No domperidone?
Who makes No domperidone?
What development phase is No domperidone in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing